Corcept Therapeutics, Inc. (CORT)
56.37
-1.93
(-3.31%)
USD |
NASDAQ |
May 15, 16:00
56.40
+0.02
(+0.04%)
After-Hours: 20:00
Corcept Therapeutics Research and Development Expense (Quarterly) : 66.26M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Merck & Co., Inc. | 11.98B |
| Supernus Pharmaceuticals, Inc. | 38.94M |
| Terns Pharmaceuticals, Inc. (DELISTED) | 18.90M |
| Assertio Holdings, Inc. | 0.454M |
| Nektar Therapeutics | 35.68M |